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Skeletal muscle requires an efﬁcient and active membrane repair system to overcome the rigours of frequent
contraction. Dysferlin is a component of that system and absence of dysferlin causes muscular dystrophy
(dysferlinopathy) characterized by adult onset muscle weakness, high serum creatine kinase levels and a
prominent inﬂammatory inﬁltrate. We have observed that dysferlinopathy patient biopsies show an excess
of immature ﬁbres and therefore investigated the role of dysferlin in muscle regeneration. Using notexin-
induced muscle damage, we have shown that regeneration is attenuated in a mouse model of dysferlinopa-
thy, with delayed removal of necrotic ﬁbres, an extended inﬂammatory phase and delayed functional
recovery. Satellite cell activation and myoblast fusion appear normal, but there is a reduction in early neutro-
phil recruitment in regenerating and also needle wounded muscle in dysferlin-deﬁcient mice. Primary mouse
dysferlinopathy myoblast cultures show reduced cytokine release upon stimulation, indicating that the
secretion of chemotactic molecules is impaired. We suggest an extension to the muscle membrane repair
model, where in addition to fusing patch repair vesicles with the sarcolemma dysferlin is also involved in
the release of chemotactic agents. Reduced neutrophil recruitment results in incomplete cycles of regener-
ation in dysferlinopathy which combines with the membrane repair deﬁcit to ultimately trigger dystrophic
pathology. This study reveals a novel pathomechanism affecting muscle regeneration and maintenance in
dysferlinopathy and highlights enhancement of the neutrophil response as a potential therapeutic avenue
in these disorders.
INTRODUCTION
Mutations in the dysferlin gene cause limb-girdle muscular
dystrophy type 2B (LGMD2B), Miyoshi myopathy (1,2) and
distal anterior compartment myopathy (3,4), collectively
known as the dysferlinopathies. These conditions present typi-
cally with adult onset, progressive muscle weakness, highly
elevated serum creatine kinase (CK) levels and a prominent
inﬂammatory inﬁltrate in skeletal muscle (4–6). Dysferlin is
named after its homology to the Caenorhabditis elegans ferti-
lity factor fer-1 (2,7) involved in maturation of spermatids by
fusing large vesicles with the plasma membrane. It is a class II
membrane protein, containing multiple C2 domains (7,8),
inferring that, like many C2 domain-containing proteins,
dysferlin is involved in vesicle fusion (2). Dysferlin interacts
with various proteins including afﬁxin, AHNAK, annexin
A1 and A2, calpain-3 and caveolin-3 (9–11). The annexins
and AHNAK are found in the enlargeosome, a calcium-
regulated vesicle capable of rapid exocytosis (12–14) and
both dysferlin and caveolin-3 trafﬁc via the late endosomal
compartment, from which the enlargeosome derives (15). A
deﬁciency of membrane resealing in a mouse model of dysfer-
linopathy is consistent with the theory that dysferlin is
involved in the fusion of vesicles from the enlargeosome
with the plasma membrane (16,17). The ‘membrane repair
hypothesis’ postulates that dysferlin is a key component of
the muscle membrane repair system, which forms vesicle
plugs over membrane lesions, maintaining cell homeostasis
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have identiﬁed a further component of the muscle resealing
apparatus, MG53, which responds early to membrane breaches
and may serve to aggregate the membrane repair complex at
the sarcolemma (18,19). Dysferlinopathy patients usually
develop muscular dystrophy in adult life, following a period
of good muscle performance. Mouse models of dysferlinopa-
thy have a mild muscle phenotype, as do MG53 knockout
animals. However, the link between the failure of membrane
repair and the ultimate development of a muscular dystrophy
remains unclear. We were therefore interested to explore
how cumulative damage might be implicated in the develop-
ment of disease and focused our attention on the next stage
of muscle response to injury, whereby a muscle ﬁbre under-
goes regeneration. This process requires multiple cell types
to work in synchrony, producing new contractile tissue in a
few days, even after massive injury (20). Signalling from
damaged tissue initiates rapid recruitment of neutrophils
from the circulation (21). After 24–48 h, signalling from neu-
trophils and satellite cell populations attract monocytes (22),
which are initially pro-inﬂammatory and phagocytose cellular
debris. Activated satellite cells then start to proliferate and
migrate to the injury site. Then, the monocyte population
switches to an anti-inﬂammatory phenotype, differentiating
into macrophages, which clear cellular debris and induce sat-
ellite cells to fuse (23). Studies have shown that the depletion
of inﬂammatory cells has a marked effect on the eventual
outcome of the regenerative process (23–26).
We demonstrate that dysferlin-deﬁcient patients show an
increase in immature ﬁbres as deﬁned by neonatal myosin
(neo-MHC) labelling, suggesting that the regenerative
process is delayed or incomplete in dysferlinopathy. Inducing
muscle damage in the C57BL/10.SJL-Dysf mouse model of
dysferlinopathy (27) demonstrates attenuated muscle regener-
ation. There is delayed early neutrophil recruitment, failure of
clearance of necrotic ﬁbres and a prolonged inﬂammatory
inﬁltrate that correlates with a delay in the recovery of con-
traction force. The cumulative result of sequential impaired
regeneration may be key to the ultimate development of a dys-
trophic phenotype in dysferlinopathy.
RESULTS
Dysferlinopathy patients show a higher number of
immature ﬁbres than muscular dystrophy controls
We assessed the number of immature ﬁbres, as deﬁned by
neo-MHC expression, in 10 molecularly conﬁrmed LGMD2B
patients from the NCG rare neuromuscular disease service
archives. Labelling on muscle sections was independently ana-
lysed blindly by two experienced investigators (R.B. and
R.C.). The average percentage of ﬁbres labelled with
neo-MHC was compared with 16 LGMD2A patients, six dys-
trophinopathy patients and six LGMD2I patients (Fig. 1).
Although the samples vary in patient age and stage of pathol-
ogy, dysferlinopathy patients have a consistently higher per-
centage of neo-MHC-positive ﬁbres (56.3%) than other
muscular dystrophies, especially LGMD2A patients (13.9%;
P , 0.01 Mann–Whitney). These ﬁbres do not show utrophin
labelling, suggesting that these are not ﬁbres at early stages of
regeneration (Fig. 1).
Muscle pathology is mild but progressive in
dysferlin-deﬁcient C57BL/10.SJL-Dysf mice
We performed a thorough characterization of muscle pathol-
ogy in the C57BL/10.SJL-Dysf mice (27) studying different
muscle groups by histochemistry up to 1 year of age. Overt
dystrophic changes are limited to speciﬁc muscle groups in
older animals (data not shown). The tibialis anterior (TA)
muscle was the target for our regeneration studies and
studied for force generation. Even at 1 year of age, there is
limited pathology in the TA, with some thickening of the peri-
mysial connective tissue and a small number of central nuclei
(Fig. 2A and B). Between 10 and 14 weeks of age, when the
majority of our studies were performed, we observed only a
small percentage of centrally localized nuclei. The limited
overt pathology in the TA at this stage allowed us to investi-
gate the effects of dysferlin deﬁciency in the absence of pre-
existing dystrophic changes and secondary effects such as
inﬂammation.
Mild muscle weakness is seen in C57BL/10.SJL-Dysf mice
We assessed C57BL/10.SJL-Dysf, C57BL/10 and mdx mice at
12–14 weeks of age using in situ force measurement. C57BL/
10.SJL-Dysf animals had a reduced speciﬁc force (median
262 kN/m
2 in C57BL/10, 232 kN/m
2 in C57BL/10.SJL-Dysf
and 178 kN/m
2 in mdx; P , 0.05 for each; Mann–Whitney,
Fig. 2C). Maximum isometric twitch and tetanic forces in
the C57BL/10.SJL-Dysf strain were not signiﬁcantly
reduced. The muscle was put through an eccentric (lengthen-
ing) contraction protocol (28), whereby a 40% lengthening
contraction is used to damage the muscle. The dysferlin-
deﬁcient muscle showed no signiﬁcant difference from
control in the recovery of force generation after one
(Fig. 2D) and two lengthening contractions (Fig. 2E), in con-
trast to mdx.
We also assessed dysferlin-deﬁcient animals following
eccentric exercise induced by exhaustive downhill running.
The exhaustion times for C57BL/10.SJL-Dysf were reduced,
although not signiﬁcantly (C57BL/10 median 45 min,
C57BL/10.SJL-Dysf 39 min, P ¼ 0.0532 Mann–Whitney).
Contrary to our previous report (27), serum CK levels were
signiﬁcantly elevated even without exercise (C57BL/10
median 480 IU/l, C57BL/10.SJL-Dysf 980 IU/l, P , 0.002
Mann–Whitney; Fig. 2F). In both strains, serum CK levels 1
day after exercise rose, returning to pre-exercise levels at
day 4, before a second peak at 7 days post-exercise
(Fig. 2F). Although this second peak is higher in C57BL/
10.SJL-Dysf suggesting a persistence of muscle damage in
this strain compared with control, the high variance in these
observations makes further conclusions tentative.
Dysferlin-deﬁcient mouse muscle is therefore slightly
weaker than control, but is not more susceptible to immediate
damage, showing none of the characteristic susceptibility to
contraction-induced injury seen in mdx.
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10.SJL-Dysf mice, with delay in recovery of muscle
function after notexin treatment
C57BL/10 and C57BL/10.SJL-Dysf mice were injected with
notexin (29,30) in the TA muscle of one hindlimb and the
animals allowed to recover for up to 28 days. Sections of the
muscle stained with H&E are shown in Figure 3A. Dysferlin-
deﬁcient muscle initially showed a lower concentration of
mononuclear cells (3 days post-injection), but there was striking
failure to resolve the inﬂammatory process, continuing beyond
the point where the muscle was repaired in control mice. Later
stage regenerating C57BL/10.SJL-Dysf muscle (7 and 14 days
post-injection) is characterized by darkly staining red ﬁbres,
which remain anuclear and appear to provide foci for the
ongoing inﬂammatory response. Alizarin red staining identiﬁes
abnormal sarcoplasmic accumulations of calcium. Such
ﬁbres persist in dysferlin-deﬁcient muscle beyond the point
where they have been cleared in the control muscle (Fig. 3A).
We conclude that notexin-induced regeneration is impaired
in the dysferlin-deﬁcient C57BL/10.SJL-Dysf mouse with
delayed removal of necrotic ﬁbres. To conﬁrm that this is a
feature of dysferlinopathy, the regeneration defect after
notexin treatment has also been demonstrated in the
Dysf
tm1-Kcam (16) dysferlin-deﬁcient strain (Supplementary
Material, Fig. S1A).
To look for correlation between the delayed removal of
necrotic cells following injury and impairment of muscle
function, in situ force measurement studies were performed
on the notexin injected TA muscles of C57BL/10 and
C57BL/10.SJL-Dysf mice after 7 and 14 days. Neither
strain had recovered full muscle function even at 14 days
post-injection. Recovery of t h es p e c i ﬁ cf o r c ew a ss i g n i ﬁ -
cantly impaired in dysferlin-deﬁcient mice at 7 days post-
notexin treatment (Fig. 3B). Speciﬁc force was reduced
from 91% of wild-type levels in the untreated to 65% of
Figure 1. Dysferlinopathy patients show an excess of neo-MHC positive ﬁbres. (A) Serial sections of a dysferlinopathy patient biopsy showing the characteristic
extensive labelling for neo-MHC without up-regulation of utrophin or laminin-a5 by immunohistochemistry. Red stars identify speciﬁc neo-MHC positive ﬁbres
in the serial sections. Scale bar is 100 mm. (B) Mean percentage of ﬁbres showing positive staining for neo-MHC in patient biopsies (+SEM). The causative
gene of the patient groups is shown under the graph. Dysferlin n ¼ 10, calpain-3 n ¼ 16, FKRP and dystrophin n ¼ 6.
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values of maximum isometric force were also signiﬁcantly
reduced at 14 days post-notexin and median values of both
maximum isometric tetanic and speciﬁc force suggested
that the recovery of these contraction parameters was also
delayed; however, the results were not statistically signiﬁ-
cant (data not shown).
Repeated cycles of degeneration/regeneration result in a
striking dystrophic phenotype in C57BL/10.SJL-Dysf mice
To further challenge the regenerative capacity of dysferlin-
deﬁcient muscles, C57BL/10.SJL-Dysf and C57BL/10 TA
muscles of female mice aged 10–12 weeks were subjected to
three rounds of notexin injection, 14 days apart. The muscles
Figure 2. Characterization of the C57BL/10.SJL-Dysf mouse. Tibialis anterior muscle from 1-year-old C57BL/10 (A) and C57BL/10.SJL-Dysf (B) stained with
van Gieson/Haematoxylin showing increased perimysial connective tissue in the dysferlin-deﬁcient mouse, but limited pathology. Scale bar 50 mm. (C) Speciﬁc
force generation from C57BL/10 (n ¼ 7), C57BL/10.SJL-Dysf (n ¼ 7) and mdx (n ¼ 4) mice. (D) Percentage drop in force following a single 40% lengthening
contraction. (E) Percentage drop in force following two lengthening 40% contractions. (F) Serum creatine kinase 0, 1, 4 and 7 days post-exhaustive exercise.
Median values are shown within the graph. Graphs show mean values (+SEM). C57BL/10 is represented by open bars, C57BL/10.SJL-Dysf by closed bars and
mdx by hatched bars.
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notexin treatment not only the C57BL/10.SJL-Dysf but also the
control muscle was severely affected, showing equal extensive
necrosis and inﬂammatory inﬁltrate (data not shown).
However, the control muscle was able to fully repair by
8 weeks post-injection, whereas muscle from C57BL/
10.SJL-Dysf showed a classical dystrophic pattern with ﬁbrous
tissue, variation in ﬁbre size, an ongoing inﬂammatory process
and darkly staining necrotic ﬁbres (Fig. 3C). We conclude that
repeated cycles of inﬂammatory insult and attenuated regener-
ation, act cumulatively to accelerate the development of a per-
sistentdystrophicphenotypeintheC57BL/10.SJL-Dysfmuscle.
Satellite cell activation and myoblast fusion during
regeneration appear normal in C57BL/10.SJL-Dysf mice
As activated satellite cells express dysferlin (31), we investi-
gated the possibility that a failure to activate the satellite
cell population was responsible for impaired regeneration in
dysferlin-deﬁcient muscle. Quantitative PCR (qPCR) analysis
of various markers of satellite cell activation and differen-
tiation, Myf5, Myog, Pax7 and Cdk1b (p27) showed no signiﬁ-
cant difference in any of these transcripts (Fig. 4A). The
inherent variability of transcript levels at 3–4 days post-
injection means that small differences at this stage would be
difﬁcult to detect without a much larger sample. However,
the general pattern of expression of satellite cell markers is
not markedly disturbed in the dysferlin-deﬁcient strain
suggesting that the defect in regeneration does not lie in an
intrinsic defect of satellite cells. Indeed, injured muscles
stained for desmin (a marker for myoblasts and early stage
myotubes) show that C57BL/10.SJL-Dysf myoblasts fuse
and form myotubes effectively (Fig. 4B). At 14 days, the
difference in the regenerative process between the two
strains appeared more to relate to failure of clearance of necro-
tic tissue than the ability to form new desmin positive ﬁbres.
Figure 3. Muscle regeneration following notexin injury is impaired in dysferlin-deﬁcient mice. (A) TA muscle from notexin injected mice after 3, 7 or 14 days of
recovery and uninjected (control) were stained with haematoxylin and eosin or alizarin Red which detects intracellular calcium. (B) Mean speciﬁc force (+SEM)
7 days following notexin injection. Signiﬁcant deﬁcit in force recovery was found in the dysferlin-deﬁcient strain (P , 0.05; n ¼ 5C 5 7 B L / 1 0 ,n ¼ 6 C57BL/
10.SJL-Dysf). (C) H&E stained sections from C57BL/10 and C57BL/10.SJL-Dysf animals untreated (control), and following a single or three consecutive
treatment(s) with notexin to induce muscle regeneration. Three injections of notexin in the C57BL/10.SJL-Dysf strain induce a marked dystrophic phenotype with
variation in ﬁbre size, inﬂammatory inﬁltration and necrotic ﬁbres, whereas the control (C57BL/10) strain is capable of effective regeneration. Scale bars 100 mm.
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during regeneration in this model.
Dysferlin-deﬁcient muscle shows early changes in the
inﬂammatory cell inﬁltrate with reduced neutrophil
recruitment following injury
Muscle sections at 3, 5 and 7 days after notexin injection were
stained for Ly-6G, a neutrophil marker (Fig. 5A) and positive
cells counted in seven random ﬁelds throughout the damaged
area. The numbers of Ly-6G–positive cells at day 3 were
signiﬁcantly reduced in dysferlin-deﬁcient animals (P ,
0.01). In order to conﬁrm the attenuation of neutrophil recruit-
ment, the inﬂammatory cell component of regenerating muscle
was analysed by ﬂow cytometry. Muscle from C57BL/
10.SJL-Dysf and control animals through the course of
notexin-induced regeneration was disaggregated, and the
inﬂammatory cells were separated on CD45 expression. In
both strains, the process of regeneration recapitulates a classi-
cal pattern with an early invasion of neutrophils, followed by a
population of pro-inﬂammatory Ly-6C
hi, F4/80
lo monocytes
recruited 1–3 days post-injection. These monocytes then
Figure 4. Satellite cell activation and fusion are not markedly perturbed during muscle regeneration in dysferlin deﬁcient mice. (A) Quantitative RT–PCR analy-
sis of transcripts involved in myogenesis and satellite cell fusion. There were no signiﬁcant differences between the C57BL/10 (open bars) and C57BL/
10.SJL-Dysf (closed bars) by two-way ANOVA. (B) Immunohistochemical analysis of desmin expression in muscle 3, 5, 7 and 14 days following
notexin-induced regeneration identiﬁes the fusing myotubes. Multiple small myotubes were present in the dysferlin deﬁcient muscle, indicating the potential
to fuse, although there was also necrotic ﬁbres and extensive inﬂammatory inﬁltration. Variability in the appearance of the periphery (left panel) versus the
centre (right panel) of the regenerating area is shown for C57BL/10.SJL-Dysf at day 7 and 14.
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C57BL/10 and C57BL/10.SJL-Dysf strains 3, 5 and 7 days after notexin-induced regeneration stained with an antibody against the neutrophil marker Ly-6G,
developed with DAB (dark brown) and counterstained with haematoxylin to show nuclei (blue). Signiﬁcantly (P , 0.01) fewer neutrophils were observed at
day 3 in the C57BL/10.SJL-Dysf strain. Scale bar is 50 mm. (B) Frequency plots of CD45-positive mononuclear cells extracted from muscle 0, 1, 3, 4 or 7
days after notexin injection in either the C57BL/10 or the C57BL/10.SJL-Dysf strain. Each dot represents a single event from the cytometer. Circles identify
the monocyte populations showing the shift from pro-inﬂammatory Ly-6C
hi/ F4-80
lo into the macrophage precursor (Ly-6C
lo/F4-80
hi). (C) Numbers of
CD45-positive cells, neutrophils and monocytes/macrophages extracted from the FACS data and normalized for mass of tissue. Signiﬁcant (P , 0.01) differ-
ences between C57BL10 (open bars) and C57BL10.SJL-Dysf (closed bars) were found for total CD45 cells at 3 days after notexin injury and numbers of invading
neutrophils at 1, 2 and 3 days after notexin injury.
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lo, F4/80
hi
macrophages, as the inﬂammatory phase is resolved 4–7
days post-injection (23). The switch from monocytes to
macrophages appears unaffected in the dysferlin-deﬁcient
mice, and the qualitative pattern of inﬂammatory cell recruit-
ment was similar in the two strains (Fig. 5B).
However, quantitative analysis of cell numbers showed a
signiﬁcant reduction in the number of neutrophils in the
C57BL/10.SJL-Dysf mice at 1, 2 and 3 days post-injection
compared with wild-type (Fig. 5C). There was also a signiﬁ-
cant reduction in the numbers of CD45-positive cells at
3 days post-injection. Monocyte populations also showed
reduction in numbers at days 1–3, as would be expected
since neutrophils secrete factors to recruit monocytes. In the
early stages of regeneration (days 1–2), this difference was
found speciﬁcally in the Ly-6C
hi monocyte population,
although this failed to reach statistical signiﬁcance. These
represent the monocytes recruited from the circulation which
then differentiate in situ (23) into the macrophage precursor
(Ly-6C
lo) population. At day 3, the Ly-6C
lo monocyte popu-
lation showed a signiﬁcant reduction in dysferlin-deﬁcient
animals (P , 0.02). This indicates a generalized failure of
monocyte recruitment with a concomitant reduction in the pro-
macrophage (Ly-6C
lo) cell type at day 3 where phagocytosis
of necrotic ﬁbres peaks in the notexin model.
Needle wounding of C57BL/10.SJL-Dysf muscle conﬁrms
a defect in neutrophil recruitment
Needle wounding is a simpler and more conﬁned event than
notexin injection and we hypothesized that impaired neutro-
phil recruitment would also be apparent in needle wounded
dysferlin-deﬁcient muscles. Four TAs from C57BL/10.SJL-
Dysf and control C57BL/10 mice were wounded with a hypo-
dermic syringe needle and the muscle collected after 6 h.
Serial sections of the muscle were immunostained for Ly-6G
to identify the initial wave of inﬁltrating neutrophils. His-
tology showed reduced neutrophil recruitment to the site of
injury in dysferlin-deﬁcient muscle (Fig. 6A), and quantiﬁ-
cation of the number of inﬁltrating neutrophils around the
site of injury conﬁrmed this observation (Fig. 6B). The neutro-
phil recruitment defect after needle wounding has also been
demonstrated in the Dysf
tm1-Kcam (16) dysferlin-deﬁcient
strain (Supplementary Material, Fig. S1B).
Reduced MCP-1 secretion by C57BL/10.SJL-Dysf
myoblasts
Since cytokines are important for inﬂammatory cell recruit-
ment, we hypothesized that dysferlin might play a role in
the release of cytokines or chemokines. Primary myoblasts
were derived from wild-type and dysferlin-deﬁcient neonatal
mice to investigate cytokine release in the two strains as a
possible explanation for poor neutrophil recruitment. The
cells were stimulated with 200 U/ml IFN-g for 24 h before
supernatant and cells were collected. MCP-1, MIP-2 and
IL-6 secreted into the medium was measured by ELISA and
normalized by total protein levels in the cell lysate. MIP-2
and IL-6 are not detectable at steady state in the medium or
the cells of murine primary myoblasts. However, there was
a highly signiﬁcant reduction in the MCP-1 released into the
medium by stimulated dysferlin-deﬁcient cells (P , 0.001)
(Fig. 7). This indicates that there is an impairment of cytokine
release in dysferlin-deﬁcient muscle cells on direct stimu-
lation. To conﬁrm that the cytokine release in response to
membrane wounding was also impaired this assay was
repeated using 0.005% saponin to induce membrane wounds.
MCP-1 secretion by dysferlin-deﬁcient cells using this tech-
nique was also signiﬁcantly (P , 0.001) impaired relative to
the control (Fig. 7).
DISCUSSION
In 2003, Bansal et al. (16) demonstrated that dysferlin-
deﬁcient myotubes have a defect in membrane repair,
leading to the hypothesis that failure to repair sarcolemmal
damage following injury causes loss of cell homeostasis and
cell death. Cumulative experience from the natural history of
dysferlinopathy in patients and animal models and now also
from the MG53 knockout demonstrates that the development
of early severe muscular dystrophy is not a feature of defective
muscle membrane repair. We became interested in a possible
perturbation of the regenerative process both because it rep-
resents a longer term response to injury and also because of
our observation of an increased number of immature ﬁbres
in dysferlinopathy patients compared with disease controls.
We believe that the patch hypothesis of dysferlin function
can be extended to put emphasis also on the content of the ves-
icles which fuse at the cell membrane after muscle injury,
including neutrophil chemotactic factors (Fig. 8). Failure of
the release of cytokines from damaged muscle could account
for the impairment of inﬂammatory cell recruitment at an
early stage of regeneration with subsequent incomplete
muscle remodelling, resulting in the persistence of inﬂamma-
tory cells and necrotic ﬁbres, and over time, the development
of muscular dystrophy.
This hypothesis is based on the known function of dysferlin
and other ferlin proteins as well as the expression pattern of
dysferlin in blood, which is restricted to the type II (non-
classical) monocyte population (data not shown). Dysferlin
is not expressed at an appreciable level in neutrophils, and
so the deﬁcient neutrophil response is unlikely to be due to
functional differences between dysferlin-deﬁcient and wild-
type neutrophils. The dysferlin positive monocyte population
is distinct from those which initially invade muscle following
injury (23), so it is unlikely that monocyte expression of dys-
ferlin is involved in the defective regeneration, since the type
II monocytes are not involved until after the resolution of the
inﬂammatory phase where regeneration of dysferlinopathic
muscle is already abnormal. The well-established function of
dysferlin in fusion of vesicles with the plasma membrane
(10,16) and the observation of reduced cytokine release by
dysferlin-deﬁcient cells provide an alternative explanation,
that part of the function of dysferlin is to release cytokines
from internal vesicles in order to attract neutrophils to the
site of injury. The model presented in Figure 8 is based on
the assumption that the primary site of dysferlin action is
the mature myoﬁbre. An equally acceptable model could be
conceived where dysferlin acts to secrete chemotactic factors
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(which derive from type II monocytes) and would also be
found at the injury site, although not in the early stages
when the neutrophil recruitment defect can already be demon-
strated. This hypothesis remains tentative until some of the
underlying assumptions have been tested.
Notexin injection is a well understood method for studying
the process of muscle regeneration in animal models
(23,30,32). Previous studies have indirectly suggested many
ways that dysferlin could be involved in regeneration, includ-
ing a possible role in satellite cell activation or fusion (31).
Our data suggest the defect is not at the level of the satellite
cell, as the expression pattern of genes involved in satellite
cell activation and differentiation are not altered, and myo-
blasts appear to fuse normally. On the other hand, we show
a signiﬁcant reduction in neutrophil recruitment and a failure
to clear necrotic ﬁbres in regenerating dysferlin-deﬁcient
muscle: in keeping with the abnormal histology, there is
reduced recovery of muscle force.
Following muscle injury, inﬂammatory cells are recruited
to the injury site in an orderly manner. Neutrophils and
monocytes coexist at the site of damage, suggesting that
they have different, complementary functions. It is known
that neutrophils produce oxidizing agents that can destroy
cell membranes in the absence of other inﬂammatory cells
(33), and blocking neutrophil function results in signiﬁcantly
diminished early tissue destruction (34). Monocytes are not
responsible for membrane disruption, but their reparative func-
tions are inhibited by the absence of neutrophils (35,36).
Therefore, speciﬁc neutrophil functions are necessary for
tissue repair and the interactions between neutrophils and
monocytes appear essential to physiological regeneration. It
is clear that the impaired neutrophil recruitment is not a con-
sequence of the delayed regenerative process, since this effect
precedes any perturbation in muscle regeneration and can also
be observed shortly after needle wounding.
There is already direct evidence that the depletion ofthe neu-
trophil population impairs and attenuates muscle regeneration
(24), leading to reduction in macrophage numbers and failure
to clear necrotic ﬁbres similar to our ﬁndings. The complete
neutropenia induced in these studies is more extreme than the
situation in dysferlinopathy, where only a partial reduction in
neutrophil recruitment is observed. The moderate reduction in
macrophage recruitment observed in our studies is also consist-
ent with these data, where total neutropenia resulted in only an
50% reduction in macrophage numbers. This is most likely
due to the existence of neutrophil independent mechanisms
of macrophage recruitment and a non-linear relationship
between neutrophil signalling and macrophage response.
The inﬂammatory phase of muscle regeneration in our
model persists beyond the stage where it has resolved in the
control animals. This is entirely consistent with the human
situation in dysferlinopathy where a persistent inﬂammatory
inﬁltrate is common (6) possibly reﬂecting a failure of
muscle remodelling following partial regeneration. We
hypothesise that both in this model system and in the dys-
trophic patients, the persistent necrotic ﬁbres provide foci
for an ongoing inﬂammatory reaction. An increasingly
pro-inﬂammatory milieu develops from successive rounds of
poor regeneration, increasing the tissue load of both necrotic
and inﬂammatory cells and directing myogenic cells towards
a ﬁbrotic fate (37,38).
We have conﬁrmed previous data (32) that the established
membrane repair defect in dysferlinopathic muscle does
not appear to cause acute exercise intolerance which is in
Figure 6. Ly-6G staining and needle wounding conﬁrm a defect in neutrophil
recruitment. (A) Needle wounded muscle from C57BL/10 and C57BL/
10.SJL-Dysf was harvested 6 h after wounding and stained with H&E and
by immunohistochemistry for the neutrophil marker Ly-6G. Scale bar is
50 mm. (B) Counts of cells per unit area conﬁrm the visual observation that
signiﬁcantly more neutrophils are present in C57BL/10 (open bars) than
C57BL/10.SJL-Dysf (closed bars) 6 h after needle wounding.
Figure 7. Dysferlin deﬁcient primary myoblasts show impaired secretion of
MCP-1 on stimulation. The concentration of MCP-1 was assayed by ELISA
in the medium of primary myoblast cells derived from neonatal C57BL/10
(open bars) and C57BL/10.SJL-Dysf (closed bars) 24 h after stimulation
with interferon gamma or treatment with 0.005% saponin. ND, not detected
(MCP-1 was below the threshold for detection in the ELISA).
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despite an apparently comparable membrane resealing defect.
Careful analysis of these animal models in the future may help
to demonstrate the relative contributions of these different pro-
teins to the process of repair and subsequent recovery. For
example, it is possible to speculate that if the reduction in
early neutrophil recruitment is speciﬁc to dysferlin deﬁciency,
the normal neutrophil response in the MG53 knockout could
contribute to the acute damage observed (18). Our ﬁnding of
slight weakness, but no susceptibility to lengthening contrac-
tions in the dysferlin-deﬁcient mice is consistent with this
interpretation and the clinical situation, where patients gener-
ally develop weakness at a late stage and following a period of
pre-symptomatic hyperCKaemia. This expanded model of
disease pathogenesis explains a number of unusual features
of the disease, including the late onset following a period of
good muscle prowess with exercise tolerance and the exten-
sive inﬂammatory process.
Previous studies have examined the role of dysferlin in
monocytes (39,40) and found evidence of an increased phago-
cytotic activity (40). However, these authors examined the
SJL/J strain and compared these animals with C57BL/6J.
Genetic differences between these strains make it difﬁcult to
conclude that a global increase in phagocytotic activity is sup-
ported, especially given the strongly pro-inﬂammatory situ-
ation in SJL/J which would a priori be expected to increase
the activity of phagocytes. Our studies using very similar
techniques in C57BL/10-SJL.Dysf indicate no signiﬁcant
difference in the phagocytotic index when compared with
the genetically equivalent C57BL/10 (data not shown).
These authors also examined phagocytes from dysferlinopathy
patients. However, in these patients, there is commonly an
ongoing inﬂammatory process in the muscle which would
also be expected to increase phagocyte activity. The assay
used, both in our laboratory and others, is a simple measure
of the phagocyte ability to engulf ﬂuorescent particles,
whereas the process that we are examining in this study (the
clearance of necrotic ﬁbres by both neutrophils and macro-
phages) is much more complex, requiring tight control in
order to initiate the orderly inﬂammatory process that degrades
damaged tissue without damaging healthy cells. We believe
that it is this cascade, rather than the process of phagocytosis
itself which is defective here. It is, however, also important to
consider that an additional factor in the resolution of regener-
ation might reside in the monocyte population, which also
express dysferlin. Dysferlin is speciﬁcally expressed in the
Ly-6C
lo, pre-macrophage population which is not recruited
to the muscle until later in the regenerative process—a
defect in this monocyte population therefore does not
explain the early neutrophil recruitment defect but requires
further investigation in the later stages of regeneration.
Although the precise mechanisms responsible for attracting
inﬂammatory cells into damaged tissues remain unclear, mice
with engineered mutations in MCP-1 or its receptor CCR2
display impaired skeletal muscle regeneration after injury
(41,42). Interestingly, not only inﬂammatory cells but also sat-
ellite cells are responsible for cytokine release (43). We
demonstrated that MCP-1 release from dysferlin-deﬁcient
myoblasts was signiﬁcantly reduced relative to wild-type. It
is already established that dysferlin translocates to the
Figure 8. Hypothetical mechanism linking membrane repair with neutrophil recruitment in normal muscle. A membrane wound (A) such as physical injury or
exercise induced tear, induces the calcium dependent fusion of vesicles with the sarcolemma (B) under the control of dysferlin. This releases vesicle contents, the
hypothesized neutrophil chemotactic factors and reseals the membrane. Dysferlin continues to induce vesicle fusion (C) to set up a chemotactic gradient which
directs neutrophils directly to the ﬁbre, and speciﬁc region of the ﬁbre, which was wounded.
Human Molecular Genetics, 2009, Vol. 18, No. 11 1985membrane in response to injury and is responsible for the
fusion of vesicles with the sarcolemma (10,16,44,45). Our
ﬁndings implicate dysferlin in the process of cytokine/
chemokine release upon muscle injury.
Establishing a link between any postulated molecular mech-
anism of disease and the end point of in vivo pathology is
crucial to the development of targeted therapeutics. Our
work emphasises failure of ongoing muscle regeneration and
maintenance in addition to the acute response to sarcolemmal
damage. Enhancement of the neutrophil response is a potential
new therapeutic avenue for dysferlinopathy.
MATERIALS AND METHODS
Patients
Patients were identiﬁed for this study through the database of
the Diagnostic and Advisory Service for Rare Neuromuscular
Diseases based at the Muscle Immuno-Analysis Unit (MIU),
Newcastle. All patients had a conﬁrmed molecular diagnosis,
had been analysed at the MIU and met ethical criteria for
inclusion within the study.
Exercise-induced injury and CK analysis
We originally obtained dysferlin-deﬁcient C57BL/
10.SJL-Dysf mice from Professor Reginald Bittner (Medical
University of Vienna). All strains of mice were housed
under standard conditions and used according to the Animal
Procedures Committee, Home Ofﬁce, UK and local rules.
To acclimatize the mice to the apparatus, mice were run
gently downhill on a treadmill inclined at 158 for 10 min at
9 m/min on day 1, then 10 min at 10 m/min on day 2 and
10 min at 10 m/min on day 3. On day 4, the mice were run
for 10 min at 10 m/min, at which point the speed was
increased within a few seconds to 16 m/min. Mice were run
to exhaustion at this speed and the time to exhaustion noted.
Blood samples were taken via the tail vein and serum isolated
for CK analysis.
In situ force measurement
This procedure was adapted from standard protocols (28,46).
Mice were anaesthetized with an intra-peritoneal injection
of hypnorm
w/hypnovel
w/water (1:1:2 by volume) at a
dosage of 10 ml/kg. Under deep anaesthesia, the distal
tendon of the TA muscle was dissected from surrounding
tissue and the tendon tied with 4.0 braided surgical silk
(Ethicon Inc.). The sciatic nerve was exposed and all its
branches cut except for the common peroneal nerve (CPN),
which innervates the TA muscle. The mouse was placed on
a heated stage (Aurora Scientiﬁc Inc.) to maintain body
temperature at 378C. The TA tendon was attached to the
lever arm of a 305C dual-mode servomotor transducer
(Aurora Scientiﬁc Inc.).
TA muscle contractions were elicited by stimulating the
distal part of CPN via bipolar platinum electrodes, using supra-
maximal square-wave pulses of 0.02 ms (701B Stimulator;
Aurora Scientiﬁc Inc.). Data acquisition and control of the ser-
vomotors were conducted using a LabView based DMC
program (Dynamic muscle control and Data Acquisition;
Aurora Scientiﬁc Inc.).
After establishing the force–frequency relationship, we
assessed the susceptibility of TA muscles to a lengthening
contraction protocol. This consisted of stimulating the
muscle at 180 Hz (the frequency that usually resulted in Po)
for 500 or 300 ms, then the muscle was lengthened by 40%
of Lo at a velocity of 2Lf/s. A second lengthening contraction
identical to the ﬁrst was administered 10 s later and maximum
isometric force was measured 1 and 15 min later. At the end of
the experiment, muscles were excised, weighed and prepared
for histological analysis.
Muscle injury and muscle preparation
Notexin (50 mla t4 mg/ml in 0.9% NaCl; Latoxan) was
injected directly into the right TA of 8- to 12-week-old
female mice using a 0.5 ml U-100 insulin syringe (the left
TA was used as a non-injected control). For multiple injec-
tions, the animals were allowed to recover for 14 days
between treatments and muscles were harvested 21 or 28
days following the ﬁnal injection. The TA muscles were
excised and rinsed in PBS and embedded in OCT. Serial
10 mm sections were used for the histological analysis or
immunohistochemical staining. Haematoxylin and eosin stain-
ing was used for morphological analysis and Alizarin Red S
was used to detect the necrotic ﬁbres. Images were taken
using an Axioplan II microscope (Carl Zeiss, Inc., USA)
with Axiovision 4.6 software (Carl Zeiss MicroImaging,
Inc.). Quantitative analysis of muscle regeneration was per-
formed on the entire injured area. Ten ﬁelds (40  objective;
Carl Zeiss MicroImaging, Inc.) were analyzed in each
mouse, representing 300–400 ﬁbres per muscle.
Immunohistochemistry
Longitudinal or transverse sections of 10 mm were cut using a
cryostat and kept at 2808C until further processing. Sections
were ﬁxed in 4% PFA/TBS for 15 min, followed by incubation
in 3% H2O2/TBS for 10 min to block endogenous peroxidase,
and blocking of endogenous biotin (Avidin/Biotin Blocking
System, DAKO). Sections were then incubated with 2%
BSA/TBS for 30 min before application of primary antibody.
Sections were incubated with one of the following primary
antibodies diluted in 2%BSA/TBS; biotinylated mouse anti-
human desmin 1:25 (ARKTM Peroxidase kit (K3954,
DAKO), clone D33, DAKO) at room temperature for
30 minutes or rat anti-mouse Ly6G 1:1000 (1A8, BD Phar-
mingen) overnight at 48C. This was followed by anti-rabbit
EnVision
þ-HRP-conjugated polymer (DAKO) or rabbit
anti-rat biotinylated secondary antibody 1:200 for
30 minutes, then Streptavidin-HRP conjugate (DAKO) for
15 minutes and DAB
þ substrate (Vector laboratories, Inc.,
Burlingame, CA) for development of peroxidase activity for
10 minutes. Counterstaining of nuclei was performed using
Harris haematoxylin (Surgipath) followed by mounting of
slides with Aquamount (VWR). Images were acquired using
a Zeiss Axioplan microscope coupled to an AxioCam
camera and the AxioVision software.
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TA muscles were harvested before injury (day 0) and 2, 3, 4, 5,
7 and 10 days post-injection with notexin and total RNA was
extracted using TRIzol, according to the manufacturer’s
instruction (Invitrogen). This was followed by reverse tran-
scription of total RNA into cDNA using the Superscript III
reverse transcriptase system, according to the manufacturer’s
instructions (Invitrogen). Relative expression levels of Pax7,
Myf5, Myog, Cdk1b (p27) and reference genes Hprt1 and
Pgk1 was determined using custom-made primer-probes
(PrimerDesign Ltd., Southampton, UK) and the qPCR reac-
tions were run on the ABI PRISMTM 7900 HT Real-Time
PCR System (Applied Biosystems, Inc.). All reactions were
run in triplicate on TA muscles (n ¼ 5) for each time point
for both C57BL/10 and C57BL/10.SJL-Dysf mice.
Raw data were extracted and analyzed in SDS2.1 (Applied
Biosystems, Inc.) using automatic detection of Ct-values, fol-
lowed by export to qBase (47). Here the Ct-values were
quality checked, all triplicates were evaluated and a run was
excluded if the difference in Ct within a triplicate .0.5. For
all analyses, the data was normalized to the expression of
Hprt1 and Pgk1 (reference gene stability was determined
using the geNorm Housekeeping gene selection kit plus
additional custom-made reference genes (PrimerDesign Ltd.)
and analyzed using the geNorm software (48), and the
results were produced as relative expression level with
lowest expression equal to one.
For the qPCR data, two-way ANOVA was used to deter-
mine if there was any statistically signiﬁcant difference in
relative expression levels over time for each analyzed
mRNA between C57BL/10 and C57BL/10.SJL-Dysf.
A P-value , 0.05 was considered signiﬁcant.
Analysis of inﬂammatory cell recruitment
Inﬂammatory cell recruitment was analysed by ﬂow cytome-
try. Mice (generally four per time point) were sacriﬁced 1,
2, 3, 4 and 7 days after notexin injection (non-injected mice
were used as controls). Fascia of the TA was removed.
Muscles were dissociated in PBS containing collagenase D
1.5 U/ml (Roche Diagnostics GmbH), dispase II 2.4 U/ml
(Roche Diagnostics GmbH) and 2.5 mM CaCl2, incubated at
378C for 1 h, ﬁltered and counted. Cells were stained with
PerCP-Cy5.5-conjugated anti-CD45 (BD Biosciences),
Alex647-conjugated anti-F4/80 (AbD Serotec) and FITC-
conjugated Ly6C (BD Biosciences) antibodies. Analysis was
performed with an LSRII cytometer (BD Biosciences). The
numbers of monocytes and neutrophils were calculated as
the total cells multiplied by the percentage of cells within
the gate. Within this population, monocyte subsets were ident-
iﬁed as either F4/80
lo/Ly6C
hi or F4/80
hi/Ly-6C
lo. Neutrophils
were identiﬁed as F4/80
2/Ly-6C
int. Total cell numbers were
normalized to TA weight.
Primary myoblast culture and cytokine release assay
Primary myoblast cultures were isolated and cultured using
standard techniques. Brieﬂy, limb muscles were carefully
removedfromtwotothreeneonatalmiceandplacedimmediately
in PBS. In a laminar ﬂow cabinet, the muscles were minced to
slurry, treated with collagen/dispase/CaCl2 solution, containing
1.5 U/ml collagenase D (Roche), 2.4 U/ml dispase II (Roche)
and 2.5 mM CaCl2, and incubated at 378C for 25 min. After cen-
trifugationfor5 minat350g,thecellswereresuspendedinHam’s
F-10 (Invitrogen) containing 20% fetal calf serum (Invitrogen),
2.5 ng/ml human basic ﬁbroblast growth factor (Promega),
100 U/ml penicillin and 100 mg/ml streptomycin. The cells
wereculturedon collagen-coatedﬂasksat 378Ci n5 %C O 2incu-
bator and the growth medium was changed every 2 days. After
four to ﬁve passages, most of the ﬁbroblasts were eliminated
from the culture and myoblasts were grown by replacing the
F-10basedgrowthmediumtoF-10/DMEM-basedprimarymyo-
blastgrowthmedium(40%ofHam’sF-10,40%ofDMEM,20%
fetal calf serum, 2.5 ng/ml basic ﬁbroblast growth factor and
100 U/ml penicillin and 100 mg/ml streptomycin). For fusion
assays, the medium was substituted with DMEM containing
5% horse serum and 100 U/ml penicillin and 100 mg/ml strepto-
mycin. Primary myoblasts were cultured in a 24 well plate for 2
days before stimulation with 200 U/ml IFN-g or wounding with
0.005% saponin. The medium and cells were harvested 24 h
after stimulation and MCP-1 concentration was analyzed by
ELISA (R&D Systems).
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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